© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 10, 2022
Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.
David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.
Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.
May 03, 2022
Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.
Veeral Sheth, MD: Promising Developments from the Past Year in Retina
David B. Glasser, MD: The Larger Implications of Telehealth in Ophthalmology
Inequities Continue to Exist in Ophthalmology Care